Amgen researchers confirm the lackluster data on the KRAS G12C drug AMG 510 reported at ESMO — but they still have a long way to go exploring options

We learned at ESMO that Amgen’s star cancer drug, the pioneering KRAS G12C player AMG 510, tended toward the unimpressive when applied outside non-small cell lung cancer. And the research team has another batch of data to back that up for ASCO. In their CodeBreak100 study, investigators reported on 25…